SAPK2 Inhibitors
1 drugsAbout SAPK2
SAPK2, or Stress-Activated Protein Kinase 2, is a protein kinase involved in intracellular signaling pathways responding to cellular stress and modulating inflammatory responses and cell survival.
SAPK2 is a potential drug target due to its role in modulating inflammatory responses; however, there is currently no genetic evidence directly linking SAPK2 to specific diseases.
SAPK2 is targeted by one FDA-approved drug, STIVARGA (Bayer), a small molecule with three indications; further research could elucidate the potential of SAPK2 inhibition in various disease contexts.
Top SAPK2 Drugs
Bayer is the only company with an approved drug targeting SAPK2.
The market is highly concentrated, suggesting high barriers to entry or limited commercial interest.
SAPK2 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets SAPK2, using small molecule modality.
The exclusive use of small molecules suggests an opportunity to explore alternative modalities like antibodies or PROTACs.
SAPK2 Clinical Trials 224 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on SAPK2. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 65 | 40 | 10 | 14 | 80% |
| Phase 2 | 127 | 50 | 24 | 53 | 68% |
| Phase 3 | 28 | 13 | 6 | 9 | 68% |
| Phase 4 | 4 | 3 | 1 | 0 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved SAPK2 drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting SAPK2. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
SAPK2 Drug Approval Timeline (2012 - 2012)
The first and only drug targeting SAPK2, STIVARGA, was approved in 2012.
The lack of recent approvals indicates a potentially saturated market or challenges in developing new SAPK2-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 132 (29 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on SAPK2. A trial counts if an approved drug acting on SAPK2 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.